David Matlin Biography and Net Worth

Director of Clene

Mr. Matlin is the Chief Executive Officer of MatlinPatterson Global Advisers LLC, a global private equity firm, which he co-founded in 2002. David was a former Managing Director at Credit Suisse First Boston and also a founding partner of Merrion Group, L.P. He currently serves on the public boards of Flagstar Bancorp, Inc. (NYSE: FBC) and U.S. Well Services, Inc. (NASDAQ: USWS), as well as privately held DermaSensor, Inc., Pristine Surgical, LLC, and Traffk, LLC. David holds a JD from the Law School of the University of California at Los Angeles and a BS in Economics from the Wharton School of the University of Pennsylvania.

What is David J. Matlin's net worth?: The estimated net worth of David J. Matlin is at least $2.10 million as of September 30th, 2024. Mr. Matlin owns 444,491 shares of Clene stock worth more than $2,097,998 as of December 23rd. This net worth approximation does not reflect any other investments that Mr. Matlin may own. Learn More about David J. Matlin's net worth.
How do I contact David J. Matlin?: The corporate mailing address for Mr. Matlin and other Clene executives is UNIT 902 9/F LUCKY BUILDING 39 WELLINGTON STREET, HONG KONG K3, . Clene can also be reached via phone at 801-676-9695 and via email at [email protected]. Learn More on David J. Matlin's contact information.
Has David J. Matlin been buying or selling shares of Clene?: David J. Matlin has not been actively trading shares of Clene during the last quarter. Learn More on David J. Matlin's trading history.
Are insiders buying or selling shares of Clene?: In the last twelve months, Clene insiders bought shares 2 times. They purchased a total of 112,819 shares worth more than $535,890.25. In the last twelve months, insiders at the sold shares 3 times. They sold a total of 2,275 shares worth more than $17,535.00. The most recent insider tranaction occured on September, 30th when insider Mark Mortenson bought 20,512 shares worth more than $97,432.00. Insiders at Clene own 25.1% of the company. Learn More about insider trades at Clene.
Information on this page was last updated on 9/30/2024.

David J. Matlin Insider Trading History at Clene

David J. Matlin Buying and Selling Activity at Clene

Clene Company Overview

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Today's Range

Now: $4.88

$4.50

$4.89

50 Day Range

MA: $4.96

$3.88

$6.38

2 Week Range

Now: $4.88

$3.82

$11.00

Volume

19,942 shs

Average Volume

74,221 shs

Market Capitalization

$40.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment

From Behind the Markets | Ad

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>